The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.
about
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerYoung age: an independent risk factor for disease-free survival in women with operable breast cancerC-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancerHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesThe potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivoPredictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patientsc-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.A novel role for 14-3-3sigma in regulating epithelial cell polarity.Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionSignal transduction in mammary tumorigenesis: a transgenic perspective.Pathogenesis, prevention, diagnosis and treatment of breast cancer.miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based studyTransgenic mouse models of human breast cancer.Oncogenes and tumor suppressor genesOverexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage.Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patientsThe significance of immunohistochemistry in the diagnosis and therapy of neoplasms.Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policyLymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast CarcinomaThe vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.Emerging drugs for non-small cell lung cancer.YB-1 drives preneoplastic progression: Insight into opportunities for cancer preventionExpression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancerAmplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma.T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumorsIntrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient.Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence.Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.Her2 positivity and race predict higher mastectomy rates: a SEER database analysis.Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan.c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
P2860
Q24641848-9239F854-4577-405D-8E8A-5C9DE3291A44Q24791855-0775E22C-4FAA-496F-84B2-6E2F0AAB3BA2Q24795406-2FC4B67C-26A8-4911-9740-5A4A45E8D149Q26822730-F7FAD469-55C4-4850-9E31-3A046F9F3D97Q26827175-2367902B-EE5A-4550-A0B7-C1CA0928FB2DQ30665854-0C253382-44CB-4F7C-9CC9-D1BEDD3C2162Q30857631-CE0E1169-92E0-479B-BAB8-8B1F8B5A2180Q33415078-DB9DD948-0FDE-4158-9477-211EACB8544EQ33415375-593D61F3-DBA1-42CF-90BD-696973233D2BQ33538427-678E78C2-7E73-4636-BBBF-6EEA9B2EFA26Q33816790-40A6E399-DFEA-4632-A089-756F0AC18F5DQ33820233-41EA195B-8290-459C-BFE8-8A26080A45C5Q33829405-CCE8CB2E-3F89-4DF3-B2D5-731F942F1D08Q33860827-8B9F3F52-4A0B-4014-9C1B-A6DACD595782Q34023647-2C4995EC-8159-4B5D-929D-FA49C192A23CQ34048535-F1A52BC7-5F0E-45D2-9037-7BE7A08B1A2DQ34129444-C0245CB8-E4E8-4EC1-9257-9942B74E531DQ34130558-17CEE599-C6E8-45EE-8D41-B9CDB964D0ADQ34149922-1C168C29-9508-4185-9AC7-C8231950AA32Q34285811-E1901A31-F34C-4711-9DC9-3B5E490578C7Q34344146-FF24A657-CBA9-4EAD-8C58-6051E653CB74Q34602545-4408287C-D5F8-46E9-93C9-CD47FE3D335FQ34897785-B113D403-0E32-4DE4-8614-66A03E5405AFQ35157568-584E1DD8-9259-41FD-8AD8-3B7A5E40B533Q35504371-A9445DC6-E6D2-4499-96B3-924AC0EB453DQ35555254-1CEB12E6-FD9E-41B5-8DA9-5D5AE76F07C3Q35581167-D72B1D4E-0590-4D11-A9E3-DBF700DA4066Q35640233-61C1694B-60C4-4EA7-A9AE-3CB0F7C5BA44Q35773929-36730274-638C-4827-8A53-B3EC9C1E196CQ35809752-DA583DF3-6601-42B2-8EE0-3F806363FC9DQ35855473-3E7DA653-3700-4986-BD88-AC4B5AAC774DQ35949083-6921D370-9B32-41B7-BD0F-1DD12F7FCE1FQ36062188-911324C6-AD91-4041-B6C5-391DD65DD77EQ36115781-49C4EC52-45A9-4603-92A7-B5FEE94FF6C0Q36135626-D6C57ADF-B0D8-4736-B2E4-FCFA4AF078A1Q36293034-88C4B9D4-10A1-4DD3-95F7-D4505DBDAC70Q36308052-4F1A9162-5D71-40EB-AF8E-3E8AAEE7CE57Q36336483-ABE11F43-177E-4962-9A69-461BFCDD2A1BQ36421775-E45798C3-EFCC-44CF-A256-1622993FBD50Q36608698-2786A8E3-8A62-4BD7-AACC-5A60E8165197
P2860
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
The c-erbB-2 proto-oncogene as ...... romolecular markers--a review.
@en
type
label
The c-erbB-2 proto-oncogene as ...... romolecular markers--a review.
@en
prefLabel
The c-erbB-2 proto-oncogene as ...... romolecular markers--a review.
@en
P1433
P1476
The c-erbB-2 proto-oncogene as ...... romolecular markers--a review.
@en
P2093
Chamness GC
P356
10.1016/0378-1119(94)00866-Q
P407
P577
1995-06-01T00:00:00Z